Exchange: NASDAQ·Updated 08:23 AM EDT
AKBA logo

AKBA Akebia Therapeutics Inc.

$0.8876
$0.009
(1.02%)
Pre-Market
Prev Close $0.8786
Reported EarningsAug 5
Mkt Cap$243.47M
Vol99,747.00

About AKBA

Akebia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with kidney diseases. The firm is also involved in the development and commercialization of drugs for the treatment of renal and metabolic disorders. Its products include Auryxia and Vafseo. The company was founded by Joseph H. Gardner, John M. Rice Jr., Michael E. Pape, Josh P. Fairbank, and Robert A. Shalwitz on February 27, 2007 and is headquartered in Cambridge, MA.
43

Bearish Sentiment

How do you feel about AKBA?

Advertisement|Remove ads.